The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy.

Autor: Gallo D; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Nicoli P; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Calabrese C; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Gaidano V; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Petiti J; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Rosso V; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Signorino E; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Carturan S; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Bot-Sartor G; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Volpe G; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Frassoni F; Department of Pediatric Hemato-Oncology and Stem Cell and Cellular Therapy Laboratory, Institute G. Gaslini, Largo G Gaslini, Genova., Saglio G; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy., Cilloni D; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2016 Jul; Vol. 5 (7), pp. 1650-3. Date of Electronic Publication: 2016 May 11.
DOI: 10.1002/cam4.735
Abstrakt: The Wilms tumor gene WT1 is a useful marker of clonal hematopoiesis and it has been shown to be a good marker of residual disease and it reflects the response to therapy. Although myelofibrosis is characterized by mutations of JAK2 and calreticulin (CALR), these mutations are not useful to monitor response to therapy. In this study we demonstrated that in patients affected by myelofibrosis WT1 correlates with the International Prognostic Scoring System (IPSS) score at diagnosis. Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity. Finally, WT1 transcript reduction can mirror a benefit of therapy on the disease burden. This study demonstrated that WT1 is a good marker for monitoring the response to therapy in patients affected by myelofibrosis.
(© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje